Ojjaara Patient Assistance Program

(momelotinib)

Key Takeaways

  1. Ojjaara® (momelotinib) is an oral prescription medication used to treat adults with intermediate- or high-risk myelofibrosis who have anemia. This includes primary myelofibrosis and secondary myelofibrosis that develops after polycythemia vera or essential thrombocythemia.
  2. Ojjaara works by inhibiting JAK1 and JAK2, as well as activin A receptor type 1 (ACVR1). By affecting these pathways, momelotinib can help address several aspects of myelofibrosis, including abnormal blood-cell production, inflammatory activity, spleen enlargement, symptoms, and anemia-related problems.
  3. Patient assistance programs may help eligible patients manage medication access and affordability.
  4. Prescription Hope helps patients navigate prescription assistance options for eligible medications. For people prescribed Ojjaara, understanding available assistance may be an important part of managing the financial side of ongoing treatment.

 

Introduction

Living with myelofibrosis can involve more than managing the disease itself. Treatment may also create financial challenges, particularly when a specialty medication such as Ojjaara is part of a long-term treatment plan.

Ojjaara contains momelotinib and is approved for adults with intermediate- or high-risk myelofibrosis and anemia. It is a once-daily oral medication that works through multiple pathways involved in myelofibrosis, including JAK1, JAK2, and ACVR1.

The cost of Ojjaara can vary considerably from one patient to another. Insurance coverage, pharmacy benefits, formulary requirements, quantity dispensed, and eligibility for assistance can all affect what a patient ultimately pays. For this reason, a single retail price figure does not necessarily reflect a patient’s actual medication cost.

Prescription Hope provides medication assistance support for eligible patients seeking more affordable access to prescription medications. Understanding patient assistance options can help patients and families navigate the financial considerations associated with specialty medication treatment.

What Is the Ojjaara Patient Assistance Program?

Understanding Ojjaara Prescription Assistance

When you’re dealing with blood cancer, the financial burden of treatment and medications can feel like a massive burden.

Due to the high cost of specialty medications, plenty of Americans feel alone and overwhelmed at the prospect of paying for their prescription.

What are patient assistance programs?

To help ease the financial burden, pharmaceutical manufacturers often provide patient assistance programs. For instance, the Ojjaara patient assistance program offers qualified patients access to affordable Ojjaara.

These programs are designed to help qualified patients access their brand-name medications at affordable rates – often at low to no cost.

However, patient assistance programs have a reputation for difficult application processes and complex bureaucratic requirements throughout.

Prescription Hope offers a powerful solution to this problem.

How Expert Advocates Help Make Ojjaara More Affordable

Personalized Medication Assistance

Getting Ojjaara cost support can mean a massive difference between completing a treatment protocol and facing a choice between bills or a prescription.

Prescription Hope’s patient assistance specialists offer qualified patients with support and advocacy throughout the Ojjaara patient assistance program application process.

Our team manages your application from start to finish. We handle document and signature collection, communication with healthcare providers and manufacturers, and any bureaucratic issues that may arise.

Ongoing Patient Support

Myelofibrosis patient assistance means that qualified patients must maintain their approval status with their program. Prescription Hope provides patients with continued administrative services, which include document and form updates, refill scheduling, yearly renewals, and issue resolution.

For as long as you are a patient with us, we are your advocates and medication access support specialists.

Ojjaara Price Comparison

vs

Prescription Hope logo

Estimated Retail Price*

$28,980.00

30-Day Supply

Prescription Hope Price

$70

Per Month, NO Matter The Retail Price

*Source: Drugs.com

Navigating Treatment Costs

To get medication access support through Prescription Hope, patients pay a simple service fee of $70.00 per month, per medication.

This service fee includes all of Prescription Hope’s services. Plus, we never include hidden charges, add-on fees, or even medication costs.

And if we can’t help a patient save on their medication costs, then they pay nothing.

Ojjaara Patient Assistance Eligibility

General Eligibility Requirements

Those curious about Ojjaara financial assistance eligibility would benefit from enrolling with Prescription Hope to find out the details.

Meanwhile, it’s good for patients to understand the general requirements of patient assistance programs.

All programs maintain strict requirements under several categories. Some categories include:

Income: Each program uses a specific income range for qualification.

Insurance: Every program differs in its acceptable insurance coverage status.

Prescription: All programs require a valid prescription for the specific medication to qualify.

Residency: Qualified patients must be legal U.S. residents.

Simple Enrollment With Expert Support

Getting Started With Enrollment

Ojjaara patient assistance enrollment through Prescription Hope takes only 6 steps:

  1. Submit Information: Fill out our online enrollment form in a matter of minutes.
  2. Advocate Contact: Once we receive your form, a patient advocate will contact you within 1-2 business days.
  3. Document Collection: After prequalification, our team will collect all necessary documents.
  4. Provider Coordination: Our team will also connect with your healthcare provider to gather required signatures.
  5. Program Submission: Once the application is ready to go, we submit your application and continue to follow up with the manufacturer.
  6. Medication Delivery: After approval, most qualified patients receive their medication within 2 weeks. All medications ship directly from the manufacturer to your door or doctor’s office.

Prescription Hope is not a pharmacy or manufacturer and does not handle medication at any time.

Understanding Ojjaara

How Ojjaara Works

Ojjaara contains momelotinib, a Janus kinase (JAK) inhibitor that affects several signaling pathways involved in myelofibrosis.

Momelotinib inhibits JAK1 and JAK2, including mutant JAK2 V617F. These enzymes are involved in signaling by cytokines and growth factors that contribute to abnormal blood-cell production and inflammatory activity associated with myelofibrosis.

Momelotinib also inhibits activin A receptor type 1, or ACVR1. This activity reduces production of the hormone hepcidin, which can increase iron availability for red blood cell production.

The medication’s activity against JAK signaling may help control abnormal signaling and inflammatory activity, while its effect on ACVR1 and hepcidin can help address aspects of anemia associated with the disease.

Ojjaara is taken orally once daily. The standard recommended dosage is 200 mg once daily, and the medication may be taken with or without food. Tablets should be swallowed whole and should not be cut, crushed, or chewed.

What Conditions Does Ojjaara Treat?

Ojjaara is FDA-approved to treat adults with intermediate- or high-risk myelofibrosis who have anemia.

The approved indication includes primary myelofibrosis, as well as secondary myelofibrosis following polycythemia vera or essential thrombocythemia.

Unlike some treatments for myelofibrosis, the FDA-approved indication for Ojjaara does not require that a patient previously received another JAK inhibitor. The approved population is adults with intermediate- or high-risk myelofibrosis and anemia.

Ojjaara is not FDA-approved for use in children.

Momelotinib has also received FDA Orphan Drug Designation for VEXAS syndrome. However, VEXAS syndrome is not an FDA-approved indication for Ojjaara. Its use for VEXAS remains investigational and should not be confused with the medication’s approved use for myelofibrosis.

Benefits of Treatment

For appropriate adults with intermediate- or high-risk myelofibrosis and anemia, Ojjaara provides a targeted oral treatment option that acts on multiple pathways involved in the disease.

Clinical studies supporting FDA approval evaluated outcomes including symptom response, spleen-volume reduction, and transfusion-related outcomes. Ojjaara may help reduce symptoms associated with myelofibrosis, reduce spleen enlargement, and address certain anemia-related outcomes.

Individual treatment responses can vary. Treatment outcomes depend on factors such as the patient’s disease characteristics, overall health, and other treatments being used.

Important Safety Information and Side Effects

Ojjaara does not carry an FDA Boxed Warning. However, its prescribing information contains several important warnings and precautions that patients and healthcare providers should understand.

Serious Infections

Ojjaara can increase the risk of serious infections, including bacterial and viral infections. Patients may be monitored for signs and symptoms of infection during treatment.

Treatment should not be initiated in patients with an active infection until the infection has been appropriately addressed. Patients with hepatitis B require appropriate evaluation and monitoring because JAK inhibitors may be associated with hepatitis B reactivation.

Thrombocytopenia and Neutropenia

Ojjaara can cause thrombocytopenia, which means a low platelet count, and neutropenia, which means a low level of certain white blood cells.

A complete blood count with platelets should be obtained before treatment, periodically during therapy, and as clinically indicated. Dosage interruption or reduction may be necessary when significant blood-count abnormalities occur.

Hepatotoxicity

Ojjaara can cause elevations in liver enzymes and, in some patients, serious liver injury.

A hepatic panel should be obtained before treatment and monitored during therapy. Current FDA labeling recommends monitoring liver tests monthly for the first six months, followed by periodic monitoring as clinically appropriate.

Clinically significant liver-test abnormalities may require treatment interruption or dosage modification.

Severe Cutaneous Adverse Reactions

Severe cutaneous adverse reactions, including toxic epidermal necrolysis (TEN), have been reported with Ojjaara.

Patients should be monitored for signs of serious skin reactions. If a severe cutaneous reaction is suspected, treatment should be interrupted while the cause is evaluated. Ojjaara should not be restarted when a severe or life-threatening reaction is determined to be related to the medication.

Major Adverse Cardiovascular Events

The FDA labeling includes a warning concerning the potential risk of major adverse cardiovascular events, or MACE. These events can include cardiovascular death, heart attack, and stroke.

This warning is based on cardiovascular safety findings associated with another JAK inhibitor in patients with rheumatoid arthritis. It does not establish that Ojjaara carries the same magnitude of risk specifically in patients with myelofibrosis.

Healthcare providers may consider individual cardiovascular risk factors when evaluating treatment, particularly for patients who currently smoke or previously smoked.

Thrombosis

JAK inhibitors may be associated with thrombotic events. Patients should be evaluated for symptoms that could indicate deep vein thrombosis, pulmonary embolism, or arterial thrombosis.

Malignancies

The FDA labeling also includes a warning concerning the potential risk of secondary malignancies based on findings associated with another JAK inhibitor.

Particular consideration may be given to patients who currently smoke or previously smoked and to patients with a known malignancy.

Symptom Exacerbation After Treatment Interruption or Discontinuation

The current FDA labeling includes a specific warning regarding worsening or return of myelofibrosis-related symptoms after Ojjaara is interrupted or discontinued.

In rare cases, serious complications may occur, including fever, breathing difficulties, low blood pressure, disseminated intravascular coagulation, and multiple-organ failure.

Patients should not interrupt or discontinue Ojjaara without discussing the decision with their healthcare provider. When treatment is stopped for reasons other than potentially life-threatening toxicity, gradual dose reduction may be considered. Supportive care and restarting Ojjaara may also be considered when clinically appropriate.

Common Side Effects

The most common adverse reactions reported in the relevant clinical studies include thrombocytopenia, hemorrhage, bacterial infection, fatigue, dizziness, diarrhea, and nausea.

Other reported adverse reactions include abdominal pain, viral infections, itching, elevated liver enzymes, fever, cough, vomiting, rash, urinary tract infections, and neutropenia.

The specific side effects experienced by a patient can vary depending on individual health status and other medications or treatments.

Pregnancy and Breastfeeding

Ojjaara may cause fetal harm. Females of reproductive potential who are not pregnant should use highly effective contraception during treatment and for 1 week after the final dose.

It is not known whether momelotinib is present in human milk. Because of the potential for serious adverse reactions in a breastfed infant, patients should not breastfeed during treatment and for at least 1 week after the final dose.

The FDA Prescribing Information lists no contraindications for Ojjaara. However, patients should discuss their medical history, medications, and other relevant health considerations with their healthcare provider before beginning treatment.

Access to Multiple Medications

Support Beyond Ojjaara

Patients taking Ojjaara often need multiple medications for their cancer treatment.

Prescription Hope’s list of hundreds of available medications for access means patients who need multiple medication assistance programs may qualify for several medications through Prescription Hope.

Our service fee of $70.00 per month, per medication means access to as many medications as you qualify for at the same low rate.

Why Choose Prescription Hope for Ojjaara Assistance

Patient-Focused Medication Support

Medication assistance for cancer can be life-changing for patients and loved ones. For 20 years, Prescription Hope has dedicated itself to supporting patients needing life-saving medication and advocating on their behalf through the patient assistance program journey.

Simplified Access to Specialty Therapies

Our access to oral oncology medication assistance and myelofibrosis medication means qualified patients no longer have to worry about the financial burden of their prescription. For $70.00 per month, per medication, qualified patients receive Prescription Hope’s support and advocacy.

Ongoing Prescription Assistance

Those who need help paying for Ojjaara and ongoing medication assistance will be glad to know that Prescription Hope doesn’t just help with the application process. Our team continues to manage administrative tasks required to maintain enrollment in the program. All for $70.00 per month, per medication.

If you’re looking for Ojjaara financial support and are interested in the Ojjaara patient assistance program, then be sure to enroll with Prescription Hope today to find out how we can help you save on your medication costs!

 

Frequently Asked Questions

It's Easy!

Submit Enrollment Form

Getting started is free and easy! Simply complete the online enrollment form. 

Receive Welcome Call

An Enrollment Specialist will reach out to you for a personalized welcome call.

We Manage The Process

Your dedicated team manages your account month after month, allowing you to focus on what matters most—your health.

Helpful Articles

Latest News & Stories

Save Money On Your Prescriptions Today!